Vitor Q. Mauad
Aracui, ES, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.
Journal: The Lancet. Haematology
Published: January 13, 2025
Critical appraisal of the inclusion criteria in: "Anticoagulant therapy in adult with COVID-19: a systematic review and meta-analysis of randomized controlled trial" for non-severe patients.
Journal: Journal of thoracic disease
Published: January 09, 2025
The Impact of Clinical Features on Survival and Relapse of Patients Diagnosed With T-cell Acute Lymphoblastic Leukemia - a Multicenter Cohort Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: October 30, 2024
COMPARATIVE STUDY OF DISTAL RADIUS FRACTURE FIXATION WITH A VOLAR PLATE VERSUS KIRSCHNER WIRES.
Journal: Acta ortopedica brasileira
Published: October 16, 2024
Evaluation of d-dimer as outcome biomarker in COVID-19 acute respiratory distress patients.
Journal: Revista do Instituto de Medicina Tropical de Sao Paulo
Published: June 24, 2024
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
Journal: The New England journal of medicine
Published: March 13, 2024
METACARPAL FRACTURES TREATMENT: COMPARASION BETWEEN KIRSCHNER WIRE AND INTRAMEDULLARY SCREW.
Journal: Acta ortopedica brasileira
Published: August 16, 2022
Does COVID-19 really impact on the oxy-hemoglobin dissociation curve?
Journal: EJHaem
Published: October 14, 2020
The Impact of Rehabilitation-oriented Virtual Reality Device in Patients With Ischemic Stroke in the Early Subacute Recovery Phase: Study Protocol for a Phase III, Single-Blinded, Randomized, Controlled Clinical Trial.
Journal: Journal of central nervous system disease
Published: April 19, 2019
Interim interleukin 6 levels correlate with progression-free survival in patients with classic Hodgkin's disease: a pilot study.
Journal: Hematology, transfusion and cell therapy
Published: June 22, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026